The problem
Heated chemotherapy only works where it reaches.
During HIPEC, temperature and drug distribution across the abdomen are measurably uneven — a problem documented in the peer-reviewed literature.
Hayhurst Medical Technologies, Inc.
Precision infrastructure for HIPEC surgical oncology
Reproducible intraoperative drug delivery and evidence-first patient selection, on one HIPEC data platform.
Everybody knows somebody who has been affected by cancer. Our mission is to make a life-extending cancer surgery more precise, more consistent, and available to every patient who needs it.
Contact HMT
Film unavailable. Showing scene stills.
From distribution to evidence
The problem
Heated chemotherapy only works where it reaches.
During HIPEC, temperature and drug distribution across the abdomen are measurably uneven — a problem documented in the peer-reviewed literature.
Mouw et al. 2022, Surgery; Cooney et al. 2024.
The device
Built to make delivery reproducible.
HMT’s multi-zone compression device is designed to automate the manual abdominal agitation surgeons perform today — the same maneuver, engineered to be even and repeatable.
Device in development. Not FDA cleared or approved. Not available for sale.
The platform
Every case strengthens the evidence.
Patient-selection decision support, CT-based PCI-scoring research, and device telemetry feed one HIPEC data platform.
Research use only — not for clinical decision-making.
Hayhurst Medical Technologies
Precise. Evidence-first. Clinical-grade.
Precision infrastructure for HIPEC surgical oncology.
Contact HMT
Traction
Built against documented milestones.
Company formation, intellectual property, grant work, engineering, and regulatory planning.
Company milestone
Formed April 20, 2026 · Kansas City, Missouri
Source: HMT company records.
Company milestone
Hayhurst Medical Technologies, Inc. — Delaware C-corporation, July 28, 2026
Source: HMT corporate records.
Company milestone
Provisional patent filed March 2026
Source: HMT company records.
Company milestone
Non-provisional patents in process — hardware and software
Source: HMT IP position, August 4, 2026.
Company milestone
Muscogee (Creek) Nation citizen-owned
Source: HMT company records.
Company milestone
Engineering, business, and regulatory partners disclosable under mutual NDA
Source: HMT company records.
Company milestone
Anticipated FDA Class II pathway; target 2028
Source: HMT regulatory planning; pre-submission.
HIPEC data platform
Delivery and evidence on one platform.
HMT is developing reproducible intraoperative drug delivery and evidence-first patient selection for HIPEC surgical oncology.
Compression device
External multi-zone closed-loop compression designed to automate manual abdominal agitation during HIPEC perfusion.
Device in development. Not FDA cleared or approved. Not available for sale.
Patient-selection decision support
A research-stage selection and referral decision-support system for CRS/HIPEC.
Research use only — not for clinical decision-making.
CT agent and PCI-scoring research
CT-based Sugarbaker PCI-scoring research is the regulated upgrade path described in HMT planning.
Research use only — not for clinical decision-making.
Evidence
Grounded in published literature.
Temperature and distribution non-uniformity during HIPEC is documented in the peer-reviewed literature (Mouw et al. 2022, Surgery; Cooney et al. 2024). HMT’s engineering and research programs are built against these measured problems.
Contact